The current user fee reauthorization package being considered by Congress for devices would aim to collect $183 million in fiscal 2018, increasing to $213 million through fiscal 2022. The fees were previously negotiated by the FDA and regulated industry, to cover medical product reviews through fiscal 2022. Both House and Senate committees have user fee hearings scheduled.
REFERENCE: FDA News; 21 MAR 2017